西洛他唑在外周血管腔内介入患者中的使用及影响
基于血管质量倡议(VQI)数据库回顾性分析245,309例外周动脉疾病(PAD)行外周血管腔内介入(PVI)的患者,其中6.6%(N=16,366)术前使用西洛他唑。经3:1倾向性匹配后纳入50,265例,西洛他唑组长期死亡率(11.5% vs 13.4%,P<0.001)和大截肢率(4.0% vs 4.7%,P=0.022)显著更低,4年无截肢生存率更高(89% vs 87%,P=0.03),但再干预、主要不良肢体事件或通畅率无显著差异。
要点
- VQI数据库中仅6.6%的PVI患者术前使用西洛他唑,作者认为使用不足。
- 匹配后西洛他唑组长期死亡率11.5% vs 13.4%,大截肢率4.0% vs 4.7%,均显著更低。
- 4年无截肢生存率西洛他唑组89% vs 87%(P=0.03),再干预和通畅率无显著差异。
核心结论
- 西洛他唑在VQI数据库中未得到充分利用,似乎与改善无截肢生存率相关。
- 作者认为,所有能耐受西洛他唑的PAD患者在PVI前应考虑使用西洛他唑治疗。
研究设计与样本
- 回顾性分析血管质量倡议(VQI)数据库中因慢性肢体威胁性缺血或跛行行PVI的PAD患者。
- 共245,309例患者接受PVI,其中6.6%(N=16,366)术前使用西洛他唑。
- 按患者人口学和合并症进行3:1倾向性匹配后,50,265例患者纳入分析,两组基线特征无差异。
- 比较术前使用西洛他唑组与未使用组的中短期和长期结局,采用Kaplan-Meier法确定结局。
主要发现
- 匹配前,西洛他唑组男性62% vs 60%(P<0.001)、白人77% vs 75%(P<0.001)、吸烟者83% vs 77%(P<0.001)比例更高。
- 匹配前,西洛他唑组糖尿病50% vs 56%(P<0.001)和充血性心力衰竭14% vs 23%(P<0.001)比例更低。
- 匹配前,西洛他唑组因跛行治疗63% vs 40%(P<0.001)、既往下肢血运重建55% vs 51%(P<0.001)比例更高,既往小截肢和大截肢10% vs 19%(P<0.001)比例更低。
- 匹配后,西洛他唑组肾脏并发症更少且更可能出院回家。
- 匹配后,西洛他唑组长期死亡率11.5% vs 13.4%(P<0.001)和大截肢率4.0% vs 4.7%(P=0.022)显著更低;再干预、主要不良肢体事件或PVI后通畅率无显著差异。
临床怎么用
- 作者认为,所有能耐受西洛他唑的PAD患者在PVI前应考虑使用西洛他唑治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cilostazol is used for the treatment of intermittent claudication. The impact of cilostazol on the outcomes of peripheral vascular interventions (PVIs) remains controversial. This study assesses the use and impact of cilostazol on patients undergoing PVI for peripheral arterial disease (PAD). METHODS: The Vascular Quality Initiative (VQI) database files for PVI were reviewed. Patients with PAD who underwent PVI for chronic limb threatening-ischemia or claudication were included and divided based on the use of cilostazol preoperatively. After propensity matching for patient demographics and comorbidities, the short-term and long-term outcomes of the 2 groups (preoperative cilostazol use versus no preoperative cilostazol use) were compared. The Kaplan-Meier method was used to determine outcomes. RESULTS: A total of 245,309 patients underwent PVI procedures and 6.6% (N = 16,366) were on cilostazol prior to intervention. Patients that received cilostazol were more likely to be male (62% vs 60%; P < 0.001), White (77% vs. 75%; P < 0.001), and smokers (83% vs. 77%; P < 0.001). They were less likely to have diabetes mellitus (50% vs. 56%; P < 0.001) and congestive heart failure (14% vs. 23%; P < 0.001). Patient on cilostazol were more likely to be treated for claudication (63% vs. 40%, P < 0.001), undergo prior lower extremity revascularization (55% vs. 51%, P < 0.001) and less likely to have undergone prior minor and major amputation (10% vs. 19%; P < 0.001) compared with patients who did not receive cilostazol. After 3:1 propensity matching, there were 50,265 patients included in the analysis with no differences in baseline characteristics. Patients on cilostazol were less likely to develop renal complications and more likely to be discharged home. Patients on cilostazol had significantly lower rates of long-term mortality (11.5% vs. 13.4%, P < 0.001 and major amputation (4.0% vs. 4.7%, P = 0.022). However, there were no significant differences in rates of reintervention, major adverse limb events, or patency after PVI. Amputation-free survival rates were significantly higher for patients on cilostazol, after 4 years of follow up (89% vs. 87%, P = 0.03). CONCLUSIONS: Cilostazol is underutilized in the VQI database and seems to be associated with improved amputation-free survival. Cilostazol therapy should be considered in all patients with PAD who can tolerate it prior to PVI.
引用
- Alameddine D, Damara FA, Pinto Rodriguez P, et al. The Use and Impact of Cilostazol on Patients Undergoing Endovascular Peripheral Interventions. Ann Vasc Surg. 2024. PMID: 38387798. doi:10.1016/j.avsg.2023.12.071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。